Jolien Tol

5.8k total citations · 2 hit papers
45 papers, 3.7k citations indexed

About

Jolien Tol is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jolien Tol has authored 45 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Jolien Tol's work include Colorectal Cancer Treatments and Studies (15 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (12 papers). Jolien Tol is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (12 papers). Jolien Tol collaborates with scholars based in Netherlands, United States and Belgium. Jolien Tol's co-authors include Cornelis J.A. Punt, Roeland E. Voorrips, Lambert P.W.J. van den Heuvel, JH van Krieken, Jan van Dalen, Jacques van der Meer, J. W. Van Ooijen, J. Han van Krieken, M. Elisa Vink-Börger and Jeroen R. Dijkstra and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jolien Tol

43 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

JoinMap® 4, Software for the calculation of genetic linkage maps in experimental populations

2006 1.5k citations Jolien Tol et al. profile →
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

2009 1.0k citations Jolien Tol, Miriam Koopman et al. profile →

Peers

Countries citing papers authored by Jolien Tol

Since Specialization

Citations

This map shows the geographic impact of Jolien Tol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jolien Tol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jolien Tol more than expected).

Fields of papers citing papers by Jolien Tol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jolien Tol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jolien Tol. The network helps show where Jolien Tol may publish in the future.

Co-authorship network of co-authors of Jolien Tol

This figure shows the co-authorship network connecting the top 25 collaborators of Jolien Tol. A scholar is included among the top collaborators of Jolien Tol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jolien Tol. Jolien Tol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial 2025 ·European Journal of Cancer ·(unknown), (unknown), Inge R. Konings, (unknown), Vincent van der Noort, E. van den Pol, (unknown), (unknown), F. Van den Berkmortel, Helga Droogendijk, Danny Houtsma, Hendrika M. Oosterkamp, (unknown), Ester Siemerink, Jolien Tol, Annette A. van Zweeden, A. Elise van Leeuwen‐Stok, Gabe S. Sonke, Agnes Jager, Hedwig M. Blommestein	1
2	Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients 2025 ·European Journal of Cancer ·(unknown), (unknown), Thiemo J. A. van Nijnatten, Sanne Engelen, Jolien Tol, Loes Kooreman, Marie-Jeanne T. F. D. Vrancken Peeters, Sabine Siesling, Adri C. Voogd, Vivianne C. G. Tjan‐Heijnen, Sandra M. E. Geurts	1
3	Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study 2025 ·The Breast ·(unknown), (unknown), Sandra M. E. Geurts, Jolien Tol, Birgit E. P. J. Vriens, (unknown), Eline Boon, M. Wouter Dercksen, Franchette van den Berkmortel, Manon J. Pepels, Natascha A. J. B. Peters, Joan B. Heijns, (unknown), (unknown), Vivianne C. G. Tjan‐Heijnen, Maaike de Boer	0
4	A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer 2024 ·European Urology Oncology ·(unknown), (unknown), (unknown), Diederik M. Somford, Paul Hamberg, Jolien Tol, (unknown), Annelieke E.C.A.B. Willemsen, Laurien M. Buffart, Roy P. C. Kessels, Niven Mehra, Inge M. van Oort, Nielka P. van Erp	4
5	The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry 2023 ·Breast Cancer Research and Treatment ·(unknown), (unknown), Ingeborg J. H. Vriens, (unknown), Sanne Engelen, Frans Erdkamp, M. Wouter Dercksen, Birgit E. P. J. Vriens, (unknown), Manon J. Pepels, (unknown), Natascha A. J. B. Peters, Jolien Tol, Joan B. Heijns, Agnès J. van de Wouw, (unknown), Sandra M. E. Geurts, Vivianne C. G. Tjan‐Heijnen	4
6	Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry 2023 ·The Lancet Regional Health - Europe ·(unknown), Sandra M. E. Geurts, Frans Erdkamp, M. Wouter Dercksen, Birgit E. P. J. Vriens, (unknown), Manon J. Pepels, (unknown), Natascha A. J. B. Peters, Jolien Tol, Joan B. Heijns, Agnès J. van de Wouw, (unknown), (unknown), Vivianne C. G. Tjan‐Heijnen	15
7	The effect of a reduced dose of enzalutamide on fatigue and cognition. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Diederik M. Somford, Paul Hamberg, Jolien Tol, (unknown), Annelieke E.C.A.B. Willemsen, Laurien M. Buffart, R.P.C. Kessels, Niven Mehra, Inge M. van Oort, Nielka P. van Erp	1
8	Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry 2023 ·Clinical Breast Cancer ·(unknown), Sandra M. E. Geurts, (unknown), (unknown), Frans Erdkamp, Joan B. Heijns, Jolien Tol, Birgit E. P. J. Vriens, (unknown), M. Wouter Dercksen, Manon J. Pepels, Natascha A. J. B. Peters, (unknown), Agnès J. van de Wouw, (unknown), (unknown), Vivianne C. G. Tjan‐Heijnen	1
9	Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry 2023 ·Breast Cancer Research and Treatment ·(unknown), Sandra M. E. Geurts, (unknown), Frans Erdkamp, Joan B. Heijns, Jolien Tol, Birgit E. P. J. Vriens, M. Wouter Dercksen, (unknown), Manon J. Pepels, (unknown), Natascha A. J. B. Peters, (unknown), Ingeborg J. H. Vriens, Vivianne C. G. Tjan‐Heijnen	7
10	De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study 2023 ·Breast Cancer Research and Treatment ·(unknown), (unknown), Liesbeth Boersma, John H. Maduro, Nicola S. Russell, Jolien Tol, Ellen G. Engelhardt, Emiel J. Rutgers, Marie-Jeanne T. F. D. Vrancken Peeters, Frederieke van Duijnhoven	8
11	Oxaliplatin infusion-related venous pain: prevention by simultaneous intravenous fluids 2020 ·BMJ Supportive & Palliative Care ·(unknown), (unknown), (unknown), Hans Pruijt, Mirrian Hilbink, Jolien Tol	1
12	HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study 2019 ·Scientific Reports ·Altuna Halilović, (unknown), Annet Simons, Marian Stevens‐Kroef, (unknown), (unknown), Bastiaan B.J. Tops, Irene Otte‐Höller, Jeroen van der Laak, Carlijn van de Water, Oliver B. Boelens, Margrethe Schlooz-Vries, Jeroen R. Dijkstra, Irıs D. Nagtegaal, Jolien Tol, (unknown), Paul N. Span, Peter Bult	10
13	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane 2018 ·Targeted Oncology ·Annelieke E.C.A.B. Willemsen, Lioe‐Fee de Geus‐Oei, Maaike de Boer, Jolien Tol, Y.J.L. Kamm, Paul C. de Jong, Marianne A. Jonker, Allert H. Vos, Willem Grootjans, (unknown), Sasja F. Mulder, Erik H.J.G. Aarntzen, Winald R. Gerritsen, Carla M.L. van Herpen, Nielka P. van Erp	9
14	Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors 2016 ·Drug Discovery Today ·Annelieke E.C.A.B. Willemsen, (unknown), Jolien Tol, Winald R. Gerritsen, Carla M.L. van Herpen, Nielka P. van Erp	38
15	Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients 2012 ·BMC Cancer ·Leonie J. Mekenkamp, Jolien Tol, Jeroen R. Dijkstra, Inge de Krijger, M. Elisa Vink-Börger, Shannon van Vliet, Steven Teerenstra, Eveline J. Kamping, Eugène T.P. Verwiel, Miriam Koopman, Gerrit A. Meijer, J. Han van Krieken, Roland P. Kuiper, Cornelis J.A. Punt, Irıs D. Nagtegaal	55
16	Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer 2011 ·Clinical Cancer Research ·Maarten J. Deenen, Jolien Tol, Artur M Burylo, Valerie D. Doodeman, Anthonius de Boer, Andrew Vincent, Henk‐Jan Guchelaar, Paul H.M. Smits, Jos H. Beijnen, Cornelis J.A. Punt, Jan H.M. Schellens, Annemieke Cats	150
17	Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer 2010 ·European Journal of Cancer ·Jan Pander, Hans Gelderblom, Ninja Antonini, Jolien Tol, J. Han van Krieken, Tahar van der Straaten, Cornelis J.A. Punt, Henk‐Jan Guchelaar	63
18	Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab 2010 ·European Journal of Cancer ·Jolien Tol, Jeroen R. Dijkstra, (unknown), Steven Teerenstra, (unknown), M. Elisa Vink-Börger, (unknown), J. Han van Krieken, Cornelis J.A. Punt, Irıs D. Nagtegaal	174
19	More is less—combining targeted therapies in metastatic colorectal cancer 2009 ·Nature Reviews Clinical Oncology ·Cornelis J.A. Punt, Jolien Tol	66
20	Current Questions in the Treatment of Advanced Colorectal Cancer: The CAIRO Studies of the Dutch Colorectal Cancer Group 2008 ·Clinical Colorectal Cancer ·Lieke H. J. Simkens, Jolien Tol, Miriam Koopman, Linda Mol, Ninja Antonini, (unknown), Cornelis J.A. Punt	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact